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Abstract
Short-chain quinones have been investigated as therapeutic molecules due to their ability to modulate cellular redox
reactions, mitochondrial electron transfer and oxidative stress, which are pathologically altered in many mitochondrial and
neuromuscular disorders. Recently, we and others described that certain short-chain quinones are able to bypass
a deficiency in complex I by shuttling electrons directly from the cytoplasm to complex III of the mitochondrial respiratory
chain to produce ATP. Although this energy rescue activity is highly interesting for the therapy of disorders associated with
complex I dysfunction, no structure-activity-relationship has been reported for short-chain quinones so far. Using a panel of
70 quinones, we observed that the capacity for this cellular energy rescue as well as their effect on lipid peroxidation was
influenced more by the physicochemical properties (in particular logD) of the whole molecule than the quinone moiety
itself. Thus, the observed correlations allow us to explain the differential biological activities and therapeutic potential of
short-chain quinones for the therapy of disorders associated with mitochondrial complex I dysfunction and/or oxidative
stress.
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Introduction
Quinones, such as coenzyme Q10 (CoQ10) or vitamin K are
a chemical class of compounds containing a quinoid ring system;
reviewed by [1,2] causing them to be involved in a vast range of
cellular redox reactions. Importantly, minor variances in their
chemical and physicochemical properties can lead to extensive
differences in their biological and pharmacological effects but no
clear structure-activity relationships (SAR) have been identified so
far. Enzymes involved in cellular quinone metabolism catalyze
mainly two different redox reactions. NADPH:cytochrome P450
reductases generate semiquinones by incomplete, one-electron
reduction [1,2]. Since semiquinones are rather unstable, there is
a high likelihood for this reaction to generate reactive oxygen
species (ROS). NAD(P)H:quinone oxidoreductases (NQOs) on the
other hand are cytosolic flavoproteins that compete with P450
reductase and catalyze the reduction of quinones and their
derivates by complete, two-electron reduction [2]. This process
leads to relatively stable hydroquinones, often also referred to as
quinols, which does not result in the formation of ROS. Thus,
NQOs are considered key detoxifying enzymes, which are induced
by stressors such as xenobiotics or oxidants [3]. NQOs have been
shown to reduce numerous pharmacologically active compounds
such as quinone epoxides, aromatic nitro and nitroso compounds,
azo dyes and Cr(VI) compounds [4], with NQO1 showing its
highest specificity towards quinones. With respect to benzoqui-
nones, NQOs are able to efficiently reduce CoQ0 [5] and CoQ1
[6,7]. These quinones are short-chain analogs of CoQ10, which is
best known for its pivotal role in mitochondrial oxidative
phosphorylation, although the functional significance of NQO-
dependent reduction of CoQ0 and CoQ1 is still unclear.
Idebenone, a benzoquinone carrying exactly the same quinone
moiety as CoQ0, CoQ1 and CoQ10, shows multiple activities in
vitro and in vivo. Most prominently associated with idebenone is its
potent antioxidant capacity as substantiated by the ability to
prevent lipid peroxidation and to protect against ROS-induced
damage in multiple systems [8–12]. Consistent with this role,
idebenone proved cytoprotective after exposure of cultured cells to
various toxic insults [8,10,11,13]. Consequently, idebenone is
under investigation as a possible treatment for disorders
characterized by excessive oxidative damage due to mitochondrial
defects. Idebenone is quickly absorbed and is well tolerated and
safe [14]. Successful treatment of a patient with Leigh syndrome
using idebenone, where high-dose CoQ10 had no effect on
respiratory function, is indicative of therapeutic levels of idebenone
in the brain [15]. Thus, idebenone has been suggested for treating
patients with mitochondrial diseases, such as mitochondrial enceph-
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Leber’s hereditary optic neuropathy (LHON) [18,19].
When Tsuruo et al [20] reported that in brain tissue of
idebenone-treated mice NQO1 activity was increased in a dose-
dependent manner, we studied this interaction in more detail [21].
We observed that idebenone and other short-chain quinones, but
not the structurally related long-chain quinone CoQ10, are
excellent substrates for reduction by NQO1 [21]. Importantly,
some of these NQO1-reduced quinones are able to donate
electrons into the mitochondrial respiratory chain to rescue
cellular adenosine triphosphate (ATP) levels under conditions of
impaired complex I function [6,21,22]. Consistent with this
cytoplasmic-mitochondrial redox cycling hypothesis, these qui-
nones also reduced extracellular lactate levels in a cell culture
model of MELAS.
Here, we compared a set of 70 short-chain quinone derivatives
with structurally modified quinone units or chain moieties. Using
this number of compounds, clear correlations of their logD values
with their ability to rescue ATP levels and activity to suppress lipid
peroxidation emerge, that connect physicochemical parameters to
their respective biological activities.
Results
Under conditions of dysfunctional complex I, it is well described
that certain short-chain quinones are capable of generating ATP
by a cytoplasmic-mitochondrial electron transfer [6,21,22]. This
electron transfer involves the reduction of quinones by cytoplasmic
NQO1 or related reductases, which is associated with a reduction
of cellular NADH levels [21]. Upon translocation to the
mitochondria these quinones are able to donate their electrons
to complex III in a antimycin-sensitive manner to increase
mitochondrial membrane potential, sustain mitochondrial respi-
ration and ATP synthesis in the presence of the complex I
inhibitor rotenone [6,21,22]. Not surprising, the effect of cellular
rotenone exposure on ATP levels is highly dependent on cell
culture medium glucose levels (Figure S1A) since under conditions
of high glucose cellular energy is predominantly generated by
glycolysis. We observed that the reduction of cellular ATP levels
by rotenone occurs within minutes under low glucose conditions
(Figure S1B). However, since only 5 minutes of incubation with
quinones is sufficient to significantly restore ATP levels after
conditions of prolonged (55 minutes) rotenone-induced ATP
deficiency [21], it can be assumed that during the time interval
before quinones are added no major cell death is induced by the
rotenone treatment itself.
Since so far, no systematic correlation of the chemical nature of
quinones to their activity profile was identified, it was of interest to
elucidate possible structure-activity relationships (SAR) using
a diverse set of compounds. Before testing multiple quinones for
this activity however, it was important to determine if the
concentration range for the described ATP-rescue effect would
differ significantly from compound to compound. For this purpose,
four quinones were selected that differed either in their quinone
moiety or the structure of the tail. When these quinones were
tested at concentrations from 0.04 to 3.3 mM it became evident
that most of them dose-dependently rescued ATP levels in vitro,
with a maximum effect at concentrations from 1 to 3.3 mM
(Figure 1). While idebenone (#1), decyl-ubiquinone (#2) and
compound #60 showed largely comparable dose-effect relation-
ships, a-tocotrienol quinone (#47) only showed a minor effect
(10% rescue) at the highest concentration (Figure 1). Strikingly,
when comparing the structures of the compounds it appeared that
the quinone moiety itself appeared to have less of an effect on the
capacity to rescue ATP levels compared to the effect of the
lipophilic tail of the compound. Decyl-ubiquinone (#2) for
example, which differs from idebenone (#1) only by the absence
of the terminal hydroxyl group of the tail, showed 30% reduced
activity at 3.3 mM compared to idebenone while at other
concentrations no differences could be detected. Even more
striking, when comparing compound #60 with a-tocotrienol
quinone (#47), which harbor the identical quinone moiety,
a significant difference in activity was evident at all concentrations
tested (Figure 1).
We then synthesized or acquired 70 related quinone com-
pounds, which largely clustered into nine structural groups that for
example contained structural motifs of idebenone, CoQ10, vitamin
E or vitamin K (Table S1). These compounds were tested for their
ability to rescue ATP levels in three different cell lines/strains to
address the reliability of the assay with regards to the species and
tissue from which the cells were derived. Comparison of results
derived from primary human myoblasts (9Te) against the activity
found in a rat myoblast cell line (L6) showed a very good
correlation (Figure 1B, R
2=0.8434). Similarly, when comparing
myoblast cells (9Te, L6) with the human immortalized hepatic cell
line HepG2, equally good correlations were obtained (Figure S1C
and D), which suggested that the capacity of quinones to rescue
ATP levels under conditions of impaired complex I were not
dependent on particular species or tissues. Thus, for all subsequent
results only data from L6 cells are shown, while the data for the
other two cell lines (9Te, HepG2), which were generally very
similar, can be found in the supplementary figures (Figures S1, S2,
S3).
The results in Figure 1A suggested that structural modifications
to the chain, which determined the physicochemical properties to
a major extent, were influencing the ATP rescue activity, rather
than modifications in the quinone moiety itself. In addition,
previous work implied that this ATP rescue activity depends on
the prior reduction of quinones, for example by NQO1 [6,21].
Therefore, we compared the reduction of this set of quinones by
recombinant NQO1 enzyme in vitro against their logD value,
which is an indicator of their hydrophilicity/lipophilicity (Figure 2).
The results demonstrate that not all quinones were equally
reduced by recombinant NQO1 in a cell-free environment. More
importantly though, a strict cut-off was evident (dashed line) at
around a logD value of 7, above which the reduction of quinones
by NQO1 was negligible, while below this threshold, little
dependence between logD and reduction by NOQ1 could be
detected.
Although previous reports indicated, using a limited number of
quinones, that the ATP rescue activity was strictly dependent on
reduction by NQO1 in cells [6,21], no clear correlation between
the reduction by NQO1 in a cell-free assay system and cellular
ATP rescue activity was found (Figure 3A). In fact, some
compounds (#37, 38, 43, 44, 63, 69, 70), despite a significant
turnover by NQO1, completely failed to protect against rotenone-
induced loss of ATP (Figure 3A, boxed red circles). At the same
time some compounds (# 10, 11, 13, 19, 59) showed significant
ATP-rescue activity in cells but hardly any reduction by NQO1 in
cell free assays (Fig. 3A, boxed blue circles). This discrepancy
suggested that other parameters in addition to the reduction by
NQO1 also influence the ability to rescue ATP levels under
conditions of impaired complex I. Surprisingly, when ATP rescue
activities were correlated to the logD values of the quinones
(Figure 3B), it emerged that in addition to the cut-off observed for
the cell-free assay at a logD value of around seven (Figure 2),
a second cut-off at a logD value of around two was detected
(dashed lines). All quinones with a logD of less than 1.9 and the
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rescue ATP levels in rat myoblasts (L6) cells, despite being
strongly reduced by NQO1 in a cell-free system (Figure 3A boxed
compounds; Figure 3B red circles). Very similar results with
regards to logD-cut off values were also observed in human
hepatic cells (HepG2) and human myoblasts (9Te) (Figure S2).
Some short chain quinones such as idebenone are described to
be potent antioxidants that prevent lipid peroxidation in multiple
systems [8–12], although at the same time some reports claim that
they can also act as pro-oxidants [23,24]. We therefore
investigated if the quinones described here also affected basal
levels of lipid peroxidation using the ratiometric fluorescent dye
BODIPY-C11 and compared it against their logD properties
(Figure 4A). Strikingly, when correlating basal levels of lipid
peroxidation against the logD values, we observed a pattern that
inversely mirrored the results of the ATP rescue/logD correlation
(Figure 3B). In the same logD window (2,logD.7), basal levels of
lipid peroxidation were significantly reduced, with idebenone (#1)
as the most potent of the 70 quinones reducing levels by more than
50%. Analogous to the results for ATP rescue (Figure 3B) the
mitochondria-targeted quinones (#69, 70) were also unable to
reduce basal levels of lipid peroxidation (Figure 4A). Despite an
antioxidant effect by the majority of quinones, clearly some
compounds increased levels of lipid peroxides, with the highest
levels observed from compounds outside the permissive logD
range (e.g. #17, 37, 62). However, there was no clear indication
that the pro-oxidative profile correlated with their logD values.
Similar results were also observed in human hepatic cells (HepG2)
and human primary myoblasts (9Te) (Figure S3). As suggested by
the similarities of the observed logD ranges in Figures 3B and 4A,
an inverse correlation (R
2=0.4709) between the ATP rescue
activity and basal levels of lipid peroxidation could be demon-
strated in rat myoblasts (L6) (Figure 4B) as well as in human
Figure 1. Efficacy of ATP rescue in the presence of rotenone by
different quinones. (A) ATP rescue by 4 different quinones was
determined in rotenone-treated rat myoblasts (L6). ATP rescue is
defined as the percentage of quinone-induced increase in ATP levels in
the presence of rotenone, relative to the ATP reduction by rotenone
alone. Bars represent the mean of 3 wells, error bars represent standard
deviation. (B) ATP rescue by different quinones is not cell type- or
species-dependent. ATP rescue by 70 quinones was determined in
primary human myoblasts (9Te), rat myoblasts (L6) and human
immortalized hepatic cells (HepG2). Correlation of values derived from
rat myoblasts (L6) and human myoblasts (9Te), are shown (R
2=0.8434).
Similar results were obtained for rat myoblasts (L6) vs. human
immortalized hepatic cells (HepG2) as well as human myoblasts (9Te)
vs. human immortalized hepatic cells (HepG2) (Figure S1). For reasons
of clarity, error bars were omitted from (B) but standard deviation (SD)
values can be found in Supplementary Table S2 which lists all results.
doi:10.1371/journal.pone.0036153.g001
Figure 2. Reduction of quinones by NQO1 in a cell free assay
system is dependent on their logD values. In vitro reduction of 70
quinone derivatives by recombinant NQO1 was correlated to their
calculated logD values. Each data point represents the mean from 2
independent experiments (see Table S1 for details about the quinones
used). For reasons of clarity, error bars were omitted from graphs but
standard deviation values can be found in Supplementary Table S2
which lists all results.
doi:10.1371/journal.pone.0036153.g002
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Discussion
Bioactivation of pharmacophores by NQO1 has been described
by multiple studies; reviewed by [25]. Most prominently, b-
lapachone and mitomycin C exhibit their biological activity only
Figure 3. Cellular ATP rescue by different quinones in the
presence of rotenone is dependent on their logD value. (A)
Cellular ATP rescue capacity was correlated to the rate of reduction by
recombinant NQO1 enzyme in a cell-free assay. Clear outliers (boxed
compounds, red circles) are either mitochondrially targeted (#69, 70) or
have logD values ,2. (Compare to Figure 3B). Similarly, some
compounds demonstrated good ATP rescue activity while being poorly
reduced by NQO1 in vitro (boxed compounds, blue circles). Of all
compounds tested, about 14% demonstrated very good (.80%) ATP
rescue activity (green circles). (B) ATP rescue ability was correlated to
the logD value of each compound. Data represent values for rat
myoblasts (L6). Similar results were obtained for human immortalized
hepatic cells (HepG2) and human myoblasts (9Te) (Figure S2). The data
represent one typical experiment out of three experiments, which
yielded similar results. The values are means 6 SD, n=3 replicate wells.
Color coding of results is analogous to (A). For reasons of clarity, error
bars were omitted from graphs but standard deviation values can be
found in Table S2, which lists all results.
doi:10.1371/journal.pone.0036153.g003
Figure 4. Effect of quinones on basal lipid peroxidation is
dependent on their logD value. (A) Cellular levels of basal lipid
peroxidation were measured using BODIPY-C11 dye and correlated with
the respective logD value. Response to DMSO was set to 100%.
Compounds #69 and 70 represent two mitochondrially targeted
idebenone molecules. The values are means 6 SD, n=3 replicate
wells. (B) Lipid peroxidation values were correlated to ATP rescue
efficiency of each quinone. Data represent values for L6 cells. Similar
results were obtained for human immortalized hepatic cells (HepG2)
and human myoblasts (9Te) (Figure S3). For reasons of clarity, the highly
prooxidative (.200%) compounds (# 36,44,52,63 64) and error bars
were omitted from graphs but standard deviation values can be found
in Supplementary Table S2, which lists all results.
doi:10.1371/journal.pone.0036153.g004
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compounds however, bioactivation by NQO1 is associated with
a toxic gain of function. In contrast, for some-short chain quinones
described here, bioactivation is associated with a protection of
cellular ATP levels under conditions of impaired complex I
function [6,21,22] and reduced levels of lipid peroxidation. To
demonstrate this effect, previous studies used quinone concentra-
tions, which were much higher than concentrations that can safely
be achieved in vivo (high mM range) [8,22]. Here, we describe for
the first time that this mechanism can be observed in vitro at
physiological concentrations, even in the low nanomolar range,
which makes short-chain quinones an attractive option for the
treatment of disorders associated with impaired mitochondrial
complex I such as mitochondrial encephalopathy, lactic acidosis and stroke-
like episodes (MELAS) [16,17] and Leber’s hereditary optic neuropathy
(LHON) [18,19]. Although NQO1-dependent electron shuttling
from the cytoplasm to the mitochondria by quinones has been
described previously [6,21,22], it was unclear whether these
reports could be seen as individual observations that are
exclusively linked to certain cellular model systems. Furthermore,
no information about a possible structure-activity relationship of
these quinones was available. The results described here indicate,
that this particular electron shuttling process and the resulting
rescue of ATP levels are not species or tissue specific responses but
instead appear to represent a mechanism found in multiple
organisms, cells and tissues. Furthermore, we described for the first
time that this effect of short-chain quinones seems to be governed
more by intrinsic physicochemical properties of the whole
molecule, such as the lipophilicity, rather than by the specific
structural features or the redox potential of the quinone moiety
alone.
Not unexpectedly, we observed an inverse correlation between
the ATP rescue activity by different quinones and their effect on
basal levels of cellular lipid peroxidation with almost identical
windows of permissive logD values. This observation could
indicate that the described activity of idebenone against lipid
peroxidation [8–12] is dependent on its physicochemical char-
acteristics and could therefore also apply to other quinones.
Consistent with our observations, Chan et al. [6] also described
that the ability of CoQ1 (#39) to rescue ATP levels is associated
with a protection of cellular glutathione (GSH) levels, thus the
capacity to rescue ATP levels appears to be tightly linked to the
cellular antioxidant capacity. Evidence that short-chain quinones
can only act as antioxidants in the reduced state [28] implies that
for dietary short-chain quinones to act as antioxidants, an efficient
reduction by cytoplasmic NQO1 or by other reductases has to be
a prerequisite. At the same time, these quinones also have to be
sufficiently lipophilic to enter cellular membranes and thus prevent
lipid peroxidation. And finally, quinones that continuously shuttle
between cytoplasmic reduction and oxidation within membranes
could act catalytically. Such a mechanism would make them
highly superior to radical scavengers that are mechanistically only
able to detoxify radicals in an equimolar ratio. In support of this, it
has to be noted that two of the quinones tested, were localized to
the mitochondria by attaching a specific targeting peptide (#69,
#70). These quinones, unable to shuttle between cytoplasm and
mitochondria, did not rescue ATP levels and also did not lower
basal levels of lipid peroxidation, despite having a permissive logD
value and consequently being efficiently reduced by NQO1. The
limited solubility in aqueous buffer of the more hydrophobic
quinones could account for the lower rates of reduction by NQO1.
For this purpose we have previously formulated the most
hydrophobic quinone of the quinones tested here, CoQ10 (#42)
by two methods commonly used (complexed with BSA and
formulated into liposomes) [21]. Under both conditions CoQ10
was not reduced by recombinant NQO1 in a cell free assay, while
at the same time idebenone was efficiently reduced. Thus, the
balance between hydrophilicity, which controls the efficient
cytoplasmic reduction by NQO1, and lipophilicity, which
determines the access to membranes is likely to be essential for
the observed rescue of ATP levels and the reduction of lipid
peroxidation. Interestingly, some of the most potent compounds
for reducing lipid peroxidation (#1, 39) are also reported to
display complex I inhibitory activity [29–31]. In particular it has
been proposed that idebenone (#1) in the reduced state has a very
slow ‘‘off’’ rate from complex I and thus blocks the CoQ10 binding
site [32]. The authors also suggested that idebenone can
additionally interact with the NADH binding site of complex I
exposed to the mitochondrial matrix. Whether these activities on
complex I contribute to the antioxidant function of short chain
quinones and how the two protective effects of short chain
quinones, ATP rescue and antioxidant function are connected in
detail will have to be elucidated in future experiments.
For our SAR investigations regarding the physicochemical
properties of short-chain quinones, we also looked at a potential
relationship between their biological effects (reduction by NQO1,
ATP rescue and protection against lipid peroxidation) and the
pKa values in addition to their logD values. However, based on
current results from the limited number of quinones with a basic
center, no clear correlation could be demonstrated, which
warrants further studies using additional quinone derivatives
specifically designed to compare compounds with similar logD
values but different pKa values.
In summary, the results described here imply that the ATP
rescue ability of short chain quinones, under conditions of
defective mitochondrial complex I, is strongly determined by the
hydrophilicity/lipophilicity (logD) of the entire molecule rather
than particular structural features. This hydrophilicity/lipophili-
city profile in turn determines the reduction by NQO1, influences
levels of lipid peroxides by their antioxidant function and finally
governs their interaction with the electron transport chain of the
mitochondria. The model described here, rationalizes for the first
time the connection of physicochemical characteristics of short-
chain quinones with their biological activities in cells and tissues
(Figure 5). Importantly, it also explains why only a very limited
number of short-chain quinones, such as idebenone, that combine
a specific set of favorable characteristics can be considered
beneficial for the treatment of mitochondrial disorders that are
associated with increased levels of ROS and reduced energy
supply.
Materials and Methods
Reagents and Chemicals
All chemical reagents, if not otherwise stated, were purchased
from Sigma (Sigma-Aldrich, Buchs, Switzerland). All cell culture
media and solutions, if not otherwise stated, were purchased from
PAA (Pasching, Austria). Most quinones were synthesized in-house
with a purity of $95% as determined by NMR and LCMS. The
synthetic pathways as well as the synthetic preparation procedures
for the test compounds listed in Table S1 of this paper were
described previously [33,34]. For all assays described, compounds
were dissolved at 10 mM (stock solution) in 100% DMSO (Acros
Organics, Belgium). Predicted LogD values (at pH 7.4) were
calculated using ACD/Labs software, (Frankfurt, Germany;
Version 12; ACD/Labs 1994–2009). The model implemented in
the software is derived from a large amount of experimental data
and allows sound extrapolations towards unknown compounds.
Features of Short-Chain Quinones
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Cell culture
Rat myoblast cells (L6, CRL-1458, ATCC, Molsheim, France)
and human hepatic cells (HepG2, 330198, CLS, Eppelheim,
Germany) were cultured under standard conditions (37uC, 5%
CO2, 90% humidity; DMEM, 1 g/l Glucose, 10% fetal bovine
serum (FBS), Penicillin-Streptomycin-Glutamine). Primary human
myoblasts (9Te) [35] were cultured in MEM EBS supplemented
with 25% M-199 EBS, 10% Hyclone FCS, 10 mg/ml insulin,
100 ng/ml EGF, 100 ng/ml FGF and Penicillin-Streptomycin-
Glutamine as described previously [35] and under conditions
described above. Significant NQO1 expression, necessary for
NQO1-dependent reduction of quinones, has been described
previously for myoblasts and HepG2 cells [21].
NQO1 dependent reduction of quinones
Reduction of quinones by recombinant NQO1 (Sigma, Buchs,
Switzerland) was measured essentially according to a modified
protocol by Ernster [36]. Reactions were performed in 1-ml
disposable cuvettes at room temperature in reaction buffer
(25 mM Tris-HCl pH 7.4, 0.7 mg/ml bovine serum albumin
(BSA), 1 mg/ml enzyme, 10 mM flavin adenine dinucleotide
(FAD), 50 mM quinone). Before the reaction was started by
addition of 200 mM NADH, the basal absorbance of the quinone
containing reaction solution was measured in a spectrophotometer
(UltrospecH 3000, Amersham Pharmaceutical Biotech, Little
Chalfont, UK). Upon the addition of NADH, the NADH
absorbance (340 nM) was measured during 60 seconds. The
decrease in NADH was estimated using the following calculation:
Abasal+A200 mM NADH2A60 sec. The assay was performed in
duplicates and the mean was used for correlations.
Quinone-dependent rescue of ATP levels
Cells were seeded at a density of 10
4 cells per well in a 96-well
plate in the corresponding culture medium (containing 1 g/l
Glucose) one day before the experiment. Cells were treated with
quinones in presence of rotenone (1 mM) for 60 minutes in
DMEM without glucose. Subsequently, cells were lysed and ATP
levels were determined as described previously [23]. Cellular ATP
levels were quantified using luminescence from the ATP-de-
pendent enzymatic oxidation of luciferin by luciferase. Briefly, cells
were lysed in a volume of 100 ml (4 mM EDTA, 0.2% Triton X-
100) for five minutes. In 96-well plates, 100 ml of ATP
measurement buffer (25 mM HEPES pH 7.25, 300 mMD -
luciferin, 5 mg/ml firefly luciferase, 75 mM DTT, 6.25 mM
MgCl2, 625 mM EDTA and 1 mg/ml BSA) was combined with
10 ml lysate to start the reaction. Luminescence was quantified
immediately using a multimode plate reader (Tecan M1000,
Tecan iControl 1.6 software; Tecan Austria GmbH, Gro ¨dig,
Austria). ATP rescue is defined as the percentage of quinone-
induced increase in ATP levels in presence of rotenone relative to
the ATP reduction by rotenone alone. The data represent one
typical experiment out of three experiments, which yielded similar
results. The values are means 6 SD, n=3 replicate wells.
Quantification of basal levels of lipid peroxidation
To assess basal levels of lipid peroxidation, cells were seeded at
a density of 2610
4 cells per well in black 96-well plates (Greiner,
Frickenhausen, Germany) in the corresponding culture medium
one day before the experiment. Cells were preincubated with
BODIPY 581/591 C11 (D3861 Invitrogen, Karlsbad, USA) by
replacing the medium with 50 ml HBSS containing 1% BODIPY
581/591 C11 for 30 minutes. The preincubation solution was
replaced with 100 ml HBSS followed by the addition of the
quinones. After one hour of quinone treatment, the cells were
washed three times with PBS and BODIPY fluorescence was
acquired immediately (Ex/Em 490/520 nM and 490/600 nM),
using a multimode plate reader. From the measured intensities, the
background intensity from control wells without cells was
subtracted before the ratio of green to red fluorescence was
calculated. The ratio obtained from DMSO treated cells was set to
100% and represents the level of basal lipid peroxidation. Due to
the known absorption characteristics for some short chain
quinones at 279 nm it is very unlikely that quinone-dependent
quenching can take place in this assay. Nevertheless, especially for
novel uncharacterized compounds, this possibility can not be
absolutely excluded.
Figure 5. Schematic representation of the requirements for
cytoplasmic-mitochondrial electron transfer and ATP rescue.
Only quinones with a logD,7 are reduced by cytoplasmic NQO1 or
other reductases. Once reduced, and depending on permissive
lipophilicity characteristics (2,logD.7), they can shuttle electrons into
the mitochondrial respiratory chain by reducing complex III or integrate
into lipid membranes to prevent lipid peroxidation. However, these
effects manifest only, if the compounds upon oxidation can return to
the cytoplasm to be reduced again, which allows them to act in
a catalytical manner. (N: no, Y: yes).
doi:10.1371/journal.pone.0036153.g005
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Figure S1 Figure S1A: HepG2 cells were incubated for
1 hour with various concentrations of glucose (0.0 to
3.2 g/l glucose). (A) The effect of rotenone treatment (6 mM) on
cellular ATP levels was evaluated for each glucose concentration.
ATP levels are expressed as percentage of DMSO-treated cells
under conditions of 3.2 g/l glucose. Cell culture medium glucose
levels did only affect the ATP levels in presence of rotenone. Bars
represent mean+SD of triplicates of one typical out of two
independent experiments. (B) Figure S1B: HepG2 cells were
incubated for 1 hour in glucose-free DMEM. Rotenone was added
at various time points to a final concentration of 6 mM. ATP levels
are expressed as percentage of the ‘0 minute rotenone’ treated
control cells (white bar). Rotenone exposure reduced ATP levels in
a time dependant manner. Bars represent mean+SD of triplicates
of one typical out of two independent experiments. (C)
Comparison of ATP rescue capacity of 70 quinone derivatives
comparing the effects in human immortalized hepatic cells
(HepG2) versus human myoblasts (9Te) (D) Comparison of ATP
rescue capacity of 70 quinone derivatives comparing the effects in
human immortalized hepatic cells (HepG2) versus rat myoblasts
(L6) (lower panel). Data is expressed as percent ATP rescue
(DMSO=0%). For reasons of clarity, error bars were omitted but
standard deviation values can be found in Supplementary Table
S2, which lists all results.
(TIF)
Figure S2 Correlation of ATP rescue capacity against
logD values of 70 quinone derivatives comparing the
effects in human immortalized hepatic cells (HepG2)
(upper panel) and human myoblasts (9Te) (lower panel).
The data represent one typical experiment out of three
experiments, which yielded similar results. The values are means
6 SD, n=3 replicate wells. For reasons of clarity, error bars were
omitted but standard deviation values can be found in Supple-
mentary Table S2, which lists all results.
(TIF)
Figure S3 Correlation of the effect on basal levels of lipid
peroxidation against logD values of 70 quinone derivatives in
human immortalized hepatic cells (HepG2) (upper panel) and
human myoblasts (9Te) (lower panel). Response to DMSO was set
to 100%. The values are means 6 SD, n=3 replicate wells. For
reasons of clarity, error bars were omitted but standard deviation
values can be found in Supplementary Table S2, which lists all
results.
(TIF)
Table S1 List of quinones tested.
(DOC)
Table S2 List of all data generated for 3 cell lines and all
assays. The following cell lines/strains were used: human
immortalized hepatic cells (HepG2), human myoblasts (9Te) and
rat myoblasts (L6).
(XLS)
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